Stocks Clock Fourth...
Health Care: Drugs
Repros Therapeutics Inc. (RPRX: NASDAQ)
$16.69 -0.32 | -1.88%
05/17/13 - 04:00 PM ET
Insider Trading
| Historical Data | Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago | 4 Mo. Ago | 5 Mo. Ago | 6 Mo. Ago |
|---|---|---|---|---|---|---|---|
| Net Insider Transaction | -2.05M | -2.05M | 2,265 | 9,964 | 9,964 | 7,699 | 0 |
| Shares Bought | 0 | 0 | 3,333 | 24,582 | 24,582 | 21,249 | 0 |
| Shares Sold | 2.05M | 2.05M | 1,068 | 14,618 | 14,618 | 13,550 | 0 |
Institutional Trading
| Historical Data | Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago | 4 Mo. Ago | 5 Mo. Ago | 6 Mo. Ago |
|---|---|---|---|---|---|---|---|
| Total Shares Held | 18.91M | 17.14M | 12.83M | 12.19M | 9.79M | 9.63M | 9.59M |
| Shares Bought | 13.53M | 11.73M | 4.13M | 3.37M | 3.28M | 3.12M | 3.11M |
| Shares Sold | 2.69M | 2.49M | 437,691 | 379,969 | 551,176 | 505,715 | 445,374 |
Portfolios with RPRX
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Under-$10 Moving Hig...
- Contributor10 Cheap Biotech Stocks Tha...
- Contributor16 Small-Cap Stocks in Dang...
- ContributorUnder $5 Stocks at Risk of ...
- UserSUPRATRADE Top Day Trader A...
- UserMicrobanks
Latest RPRX Headlines from TheStreet
- Repros Reports Issuance Of Two Additional U.S. Androxal(R) Patents 04.10.13 | 12:04 pm
- The Five Dumbest Things on Wall Street: April 5
04.05.13 | 06:04 am - Repros CEO: My Testosterone Drug Helped Gay Cubans Have Lots of Sex 03.28.13 | 12:03 pm
- Repros Reports Both Primary Endpoints Successfully Met In First Pivotal Study Of Androxal(R) 03.27.13 | 08:03 pm
- American Urological Association (AUA) Accepts Androxal(R) Versus Topical Gel Comparative Study For Podium Presentation At Annual Meeting 03.25.13 | 10:03 am
- Repros Therapeutics Inc.(R) Reports Fourth Quarter And Year End 2012 Financial Results 03.18.13 | 09:03 am
- FDA Grants Repros An End Of Phase 2 Meeting In Late May To Discuss Proellex(R)-V Phase 3 Study Design 02.28.13 | 09:02 am
- Repros Reports FDA Recommends Pivotal Study ZA-301 Of Androxal(R) To Be Completed As Originally Planned 02.21.13 | 07:02 am
- Repros Therapeutics Corporate Update 02.11.13 | 09:02 am
- Repros Updates Guidance For Top Line Results From First Pivotal Androxal(R) Study To Q3 2013 01.28.13 | 06:01 am
Press Releases for RPRX
- Repros® Announces Dismissal Of Class Action Lawsuits - Business Wire 03.03.11 | 05:03 pm
- Repros Therapeutics® Announces Pricing Of Public Offering Of Common Stock And Warrants - Business Wire 02.03.11 | 03:02 pm
- Repros Therapeutics® Receives IRB Approval To Commence Phase IIb Study Of Androxal® In The Treatment Of Secondary Hypogonadism - Business Wire 01.03.11 | 09:01 am
- Reanalysis By Outside Statistician Shows Androxal® Provides Statistically Significant Improvement In Testosterone Levels In Men With Male Hormone Levels ≤ 250 Ng/dL - Business Wire 12.28.10 | 09:12 am
- Vaginal Delivery Of Repros’® Proellex® Bypasses First Pass Liver Effects And Achieves Greater Signals Of Efficacy At Significantly Lower Exposure - Business Wire 12.27.10 | 09:12 am
- Repros® Therapeutics Submits Data To The FDA Supporting Morning Assessment Of Testosterone For Men Treated With Androxal® As Indicative Of Average And Maximum Levels Attained - Business Wire 12.23.10 | 11:12 am
- Repros® Therapeutics Prepares To Commence Dosing In Second Cohort In Low Dose Proellex® Study - Business Wire 12.16.10 | 12:12 pm
- Repros Therapeutics Inc.® Reports Third Quarter 2010 Financial Results And Provides Corporate Update - Business Wire 11.10.10 | 06:11 am
- Repros® Announces Reverse Stock Split Effective On Nasdaq October 15, 2010 - Business Wire 10.14.10 | 08:10 pm
- FDA Grants Type B Meeting To Be Held November 8, 2010 To Discuss Phase III Protocols For Androxal® - Business Wire 09.30.10 | 06:09 am
Partner Headlines for RPRX
- Shorts Are Covering These 4 Highly Shorted, Cash-Rich Small Caps - Seeking Alpha 04.23.13 | 09:04 am
- Analysts: BlackBerry Rates Were Unimpressive and 4 New Opinions Investors Must Read Now - Wall St. Cheat Sheet 04.01.13 | 11:04 am
- Analysts: BlackBerry Rates Were Unimpressive and 4 New Opinions Investors Must Read Now - Wall St. Cheat Sheet 04.01.13 | 11:04 am
- Insiders Love These 3 Highly Shorted Healthcare Stocks - Seeking Alpha 01.23.13 | 09:01 am
- A Pullback Would Be Healthy For Repros Therapeutics - Seeking Alpha 09.20.12 | 09:09 am
- Update on Repros' Androxal - Analyst Blog - NASDAQ 09.14.12 | 09:09 pm
- Update on Repros' Androxal - Analyst Blog - Zacks 09.14.12 | 06:09 pm
- Earnings Miss at Repros - Analyst Blog - NASDAQ 08.17.12 | 06:08 pm
- A Closer Look At Repros Therapeutics - Seeking Alpha 07.29.12 | 07:07 am
- Four Biotechs to Watch Early This Week - Seeking Alpha 03.06.11 | 08:03 am
